Cyrus Therapeutics Inc. has designed molecular glue degraders comprising a cereblon (CRBN)-binding moiety acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers potentially useful for the treatment of cancer.